Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2015

01-04-2015 | Research

A Chinese herbal Formula, Chang-Wei-Qin, Synergistically Enhances Antitumor Effect of Oxaliplatin

Authors: Yong Zhang, Qiang Zhang, Zhongze Fan, Jue Sun, Xulin Liu, Lingling Cheng, Ao Li, Jianhua Xu

Published in: Pathology & Oncology Research | Issue 2/2015

Login to get access

Abstract

Chang-Wei-Qing (CWQ), a Chinese herbal formula, has long been employed clinically to treat cancers. In this study, we investigated the synergistic effect of CWQ with oxaliplatin (OXA) on the tumor growth inhibition of orthotopic transplanted colon cancer and explored the underlying mechanism. By generating the orthotopic transplanted nude mouse model of human colon carcinoma, we found that (1) CWQ enhanced OXA-mediated tumor suppression by 4.25-fold. (2) The body weights of nude mice in CWQ group and combination group were increased. (3) The survival time of tumor-bearing nude mice was dramatically improved in CWQ and CWQ/OXA group. (4) CWQ could restore OXA-mediated deregulation of copper transporter genes, hCTR1, ATP7A and ATP7B. (5) OXA-induced drug resistance index for OXA, 5-FU, HCPT and THP were 7.59, 4.28, 5.78 and 4.50 respectively, while the reversal index by combined CWQ treatment were 6.57, 2.61, 4.97 and 3.10, respectively. Our study demonstrates that the repeated intraperitoneal injection of OXA can induce multi-drug resistance of orthotopic transplanted nude mouse model of human colon carcinoma. The CWQ treatment can alleviate OXA-triggered side effects and reverse platinum drug resistance via up-regulation of hCTR1 expression and down-regulation of ATP7A and ATP7B levels.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA. Cancer J Clin 61(2):69–90CrossRef
2.
Yang Y, Cai, Q, Zou D, Yang L (2013) Advances of molecular targeted drugs in the treatment of advanced colorectal cancer. Chinese J Cancer Biother 20(2):247–250
3.
Shiragami R, Murata S, Kosugi C, Tezuka T, Yamazaki M, Hirano A, Yoshimura Y, Suzuki M, Shuto K, Koda K (2013) Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells. Int J Oncol 43(2):431–438PubMed
4.
McCleary NJ, Odejide O, Szymonifka J, Ryan D, Hezel A, Meyerhardt JA (2013) Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. Clin Colorectal Cancer 12(1):62–69CrossRefPubMedCentralPubMed
5.
Gordon MA, Zhang W, Yang D, Iqbal S, El-Khouiery A, Nagashima F, Lurje G, Labonte M, Wilson P, Sherrod A et al (2011) Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics 12(1):27–39CrossRefPubMed
6.
Inoue Y, Matsumoto H, Yamada S, Kawai K, Suemizu H, Gika M, Takanami I, Iwazaki M, Nakamura M (2010) Association of ATP7A expression and in vitro sensitivity to cisplatin in non-small cell lung cancer. Oncol Lett 1(5):837–840CrossRefPubMedCentralPubMed
7.
Dmitriev OY (2011) Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B. Biochem Cell biol = Biochimie et biologie cellulaire 89(2):138––147CrossRef
8.
Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW, Liu HS, Su WC (2012) Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 75(2):228–234CrossRefPubMedCentralPubMed
9.
Kuo MT, Fu S, Savaraj N, Chen HH (2012) Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res 72(18):4616–4621CrossRefPubMedCentralPubMed
10.
Yoshida H, Teramae M, Yamauchi M, Fukuda T, Yasui T, Sumi T, Honda K, Ishiko O (2013) Association of copper transporter expression with platinum resistance in epithelial ovarian cancer. Anticancer Res 33(4):1409–1414PubMed
11.
Howell SB, Safaei R, Larson CA, Sailor MJ (2010) Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 77(6):887–894CrossRefPubMedCentralPubMed
12.
Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T et al (2000) Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60(5):1312–1316PubMed
13.
Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB (2003) The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 64(2):466–473CrossRefPubMed
14.
Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O’Rourke M, Brenckman W, Tilton R, Liu SH, Jiang Z et al (2011) A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 10(2):85–96CrossRefPubMed
15.
Wang TC, Fang CN, Shen CC, Wei HY, Weng YP, Lin JY, Hsieh-Li HM, Lee CY (2012) Yang-Dan-Tang, Identified from 15 Chinese Herbal Formulae. Inhibits Human Lung Cancer Cell Proliferation via Cell Cycle Arrest Evidence-based complementary and alternative medicine : eCAM 2012:276032PubMedCentralPubMed
16.
Zheng Z, Cho WC, Xu L, Wang J, Sze DM (2013) Lessons learnt from evidence-based approach of using chinese herbal medicines in liver cancer. Evid-Based Complement Alternat Med : eCAM 2013:656351PubMedCentralPubMed
17.
Maimon Y, Karaush V, Yaal-Hahoshen N, Ben-Yosef R, Ron I, Vexler A, Lev-Ari S (2010) Effect of Chinese herbal therapy on breast cancer adenocarcinoma cell lines. J Int Med Res 38(6):2033–2039CrossRefPubMed
18.
Shi Y, Jin, H, Wang Y, Yi J, Liu C (2013) Rat Serum Containing of Buzhong Yiqi Decoction Reverse Chemotherapeutic Resistance in A549/DDP Cells by Down-regulating Expression Levels of mTOR. Chinese J Exp Tradit Med Formulae 19(9):215–219
19.
Jia QA, Ren ZG, Bu Y, Wang ZM, Zhang QB, Liang L, Jiang XM, Tang ZY (2012) Herbal Compound “Songyou Yin” Renders Hepatocellular Carcinoma Sensitive to Oxaliplatin through Inhibition of Stemness. Evid-Based Complement Alternat Med : eCAM 2012:908601PubMedCentralPubMed
20.
Zhang Y, Sun XW, Xu JH, Lu H, Fan ZZ, Sun J, Zhang XX (2012) 2012. Zhong xi yi jie he xue bao = J Chin Integr Med 10(8):901–910CrossRef
21.
Gao QT, Cheung JK, Li J, Chu GK, Duan R, Cheung AW, Zhao KJ, Dong TT, Tsim KW (2006) A Chinese herbal decoction, Danggui Buxue Tang, prepared from Radix Astragali and Radix Angelicae Sinensis stimulates the immune responses. Planta Med 72(13):1227–1231CrossRefPubMed
22.
23.
Xu J, Fan Z, Sun J, Zhu M, Fei R, Han J (2007) Effects of“Chang Wei Qing”in Treating Advanced Gastrointestinal Cancer and Its Effects on Periphereal Blood MDR1 mRNA. Shanghai J Tradit Chin Med 41(5):40–42
24.
Zhang Y, Xu J, Sun J (2010) Clinical study of Jianpijiedu-Decoction plus FOLFOX4 regimen in the treatm ent of advanced colorectal cancer. Glob Tradit Chin Med 3(2):117–120
25.
Nakagawa T, Inoue Y, Kodama H, Yamazaki H, Kawai K, Suemizu H, Masuda R, Iwazaki M, Yamada S, Ueyama Y et al (2008) Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol Rep 20(2):265–270PubMed
26.
Li J, Fan ZZ, Sun J, Xu JH (2011) In vitro antimetastatic effect of Changweiqing through antiinvasion of hypoxic colorectal carcinoma LoVo cells. Chin J Integr Med 17(7):517–524CrossRefPubMed
27.
Xu JH, Deng WL, Fan ZZ (2010) [Effects of changwelqing on nuclear translocation of Y-box binding protein-1 and expression of P-glycoprotein in human colon cancer cell line with drug-resistance induced by vincristine]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chin J Integr Tradit West Med / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban 30(7):743–747
28.
Abraham EH, Prat AG, Gerweck L, Seneveratne T, Arceci RJ, Kramer R, Guidotti G, Cantiello HF (1993) The multidrug resistance (mdr1) gene product functions as an ATP channel. Proc Natl Acad Sci U S A 90(1):312–316CrossRefPubMedCentralPubMed
29.
Mishima M, Samimi G, Kondo A, Lin X, Howell SB (2002) The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 38(10):1405–1412CrossRefPubMed
30.
31.
Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res: Off J Am Assoc Cancer Res 14(5):1291–1295CrossRef
32.
Lin H, Sun G, Qin F, Cao Y, Wang X, Chen J, Wang X, Huang H (2013) A Randomized, Double-blinded, Drug-controlled and Multicentre Clinical Trial of Chemotherapy Assisted with Jinlong Capsule on Gastric Cancer. Cancer Res Prev Treat 40(1):12–15
33.
Hu J, Feng Y, Cao K (2011) Immunoregulation of Yiyuan Huoxue Tang in Malignant Tumor Patients. Chinese Journal of Experimental Traditional Medical Formulae 17(21):245–247
34.
Martinez-Balibrea E, Martinez-Cardus A, Musulen E, Gines A, Manzano JL, Aranda E, Plasencia C, Neamati N, Abad A (2009) Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int J Cancer J Int du cancer 124(12):2905–2910CrossRef
Metadata
Title
A Chinese herbal Formula, Chang-Wei-Qin, Synergistically Enhances Antitumor Effect of Oxaliplatin
Authors
Yong Zhang
Qiang Zhang
Zhongze Fan
Jue Sun
Xulin Liu
Lingling Cheng
Ao Li
Jianhua Xu
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-014-9831-5

Other articles of this Issue 2/2015

Pathology & Oncology Research 2/2015 Go to the issue

Research

Immunophenotype and Human Papillomavirus Status of Serous Adenocarcinoma of the Uterine Cervix

Research

Association of P53 (−16ins-Pro) Haplotype with the Decreased Risk of Differentiated Thyroid Carcinoma in Iranian-Azeri Patients

Research

Tumor Necrosis Factor Alpha (−238 / −308) and TNFRII-VNTR (−322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians

Research

Replication Study for the Association of Seven Genome- Gwas-Identified Loci With Susceptibility to Ovarian Cancer in the Polish Population

Research

Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver

Research

Prolactin and Prolactin Receptor Expression in Cervical Intraepithelial Neoplasia and Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits